Subscribe To

Price Alert Latest News Economic Calendar News

EXAI / Exscientia's AI-Powered Drug Discovery Platform Is The Future Of Precision Medicine

Exscientia's AI-driven drug discovery platform has positioned the company at the forefront of precision medicine, revolutionizing the way new therapies are developed. Exscientia's pipeline has precision oncology programs, such as EXS74539 and EXS73565, along with the initiation of Phase 1/2 trials for A2A receptor antagonist EXS21546. Read More

Demo Live Account See Partner Details

Content Topics

Exscientia

Ai

Powered

Drug

Discovery

Platform

Future

Exscientia s

Ai powered

Precision

Medicine

Stock

EXAI

Posted: May 18 2023, 01:44

Author Name: Seeking Alpha

EXAI News

By Zacks Investment Research
October 25, 2023

New Strong Buy Stocks for October 25th

RKDA, GHRS, GPS, RITM and EXAI have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2023.

By Zacks Investment Research
October 12, 2023

Exscientia PLC Sponsored ADR (EXAI) Stock Jumps 13.5%: Will It Continue to Soar?

Exscientia PLC Sponsored ADR (EXAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revision

By Zacks Investment Research
September 21, 2023

Down -33.28% in 4 Weeks, Here's Why Exscientia PLC Sponsored ADR (EXAI) Looks Ripe for a Turnaround

Exscientia PLC Sponsored ADR (EXAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with stro

By Seeking Alpha
September 20, 2023

Exscientia: Merck Deal Further Cements Industry Positioning, Reiterate Buy

Exscientia plc has partnered with Merck KGaA for AI-powered drug discovery in complex disease segments, solidifying its industry positioning. AI is ga

By Proactive Investors
September 20, 2023

Exscientia stock surges on Merck KGaA partnership

Exscientia PLC shares climbed as much as 30% in pre-market trading on Wednesday after the precision-medicine company announced a new, multi-year coll

By Market Watch
September 20, 2023

Exscientia's stock rockets toward a record gain after AI-driven drug discovery collaboration with Germany's Merck KGaA

The U.S.-listed shares of Exscientia PLC EXAI soared 28.5% toward a record one-day gain, and enough to pace all premarket gainers on major U.S. exchan

By InvestorPlace
September 7, 2023

3 Med Tech Stocks That the AI Boom Will Only Help

Med tech stocks are ripe for growth due to the advent of artificial intelligence ( AI ). AI is going to improve healthcare overall.

By InvestorPlace
August 4, 2023

3 AI Stocks Billionaires Are Loading Up On

Many investors, including a significant number of very wealthy individuals and institutions, are becoming enthralled with AI stocks. According to Gold

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.